ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

The Quick Take
SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate...
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.


